Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Scribe Therapeutics Inc. | INDUSTRY |
Not provided
Not provided
Not provided
STX-1150 is an investigational therapy designed to lower LDL-C by silencing a gene called PCSK9 in the liver. STX-1150 does not edit or permanently change the gene. STX-1150 comprises an mRNA and guide RNA (gRNA) delivered via lipid nanoparticles (LNP) for intravenous infusion. The mRNA produces a protein that switches off the PCSK9 gene expression without altering the DNA sequence. This process leverages natural mechanisms that regulate gene activity.
The study will enroll up to 64 participants with elevated LDL-C across sites in Australia and New Zealand. The follow-up period will be up to 1- year post-treatment.
STX-1150 is an investigational product designed to epigenetically silence the PCSK9 gene. It comprises an mRNA and a guide RNA (gRNA) delivered in a lipid nanoparticle (LNP) for intravenous (IV) infusion.
STX-1150 epigenetically silences the expression of the PCSK9 gene in the liver, thereby reducing circulating PCSK9 and LDL-C levels. The active components, an mRNA and a gRNA are encapsulated in lipid nanoparticles (LNPs) for targeted hepatic delivery. The gRNA precisely guides the complex to a specific locus within the PCSK9 gene promoter.
By reducing PCSK9 expression, STX-1150 prevents the degradation of LDL receptors (LDL-R), leading to increased LDL-R levels on hepatocytes and enhanced clearance of LDL-C from the bloodstream. This targeted and durable epigenetic silencing represents a promising therapeutic strategy for long-term LDL-C reduction, particularly benefiting patients with elevated LDL-C or a high risk for Atherosclerotic Cardiovascular Disease (ASCVD).
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Arm 1 | Experimental | Part 1: An open-label, single ascending dose will serve to identify the Dose-Limiting Toxicities (DLTs) and Optimal Biological Dose (OBD) of STX-1150. Part 2: Following Part 1, an open-label, single or multi-dose expansion of the OBD cohort will be conducted to further characterize the effect of STX-1150 and obtain additional safety data at the OBD. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| STX-1150 | Drug | Drug: STX-1150 is an investigational product designed to epigenetically silence the PCSK9 gene. Epigenome modulation offers a way to silence genes without changing their underlying DNA sequence. |
| Measure | Description | Time Frame |
|---|---|---|
| Incidence and Severity of Treatment-Emergent Adverse Events (TEAEs) | Up to Week 52 from administration of STX-1150 | |
| Incidence and Severity of Serious Adverse Events (SAEs) | Up to Week 52 from administration of STX-1150 | |
| Incidence and Severity of Adverse Events of Special Interest (AESI) | Up to Week 52 from administration of STX-1150 |
| Measure | Description | Time Frame |
|---|---|---|
| Incidence of dose-limiting toxicities (DLTs) | Within 14 days from administration of STX-1150 | |
| Percent Change from Baseline in Plasma PCSK9 Concentration | Up to Week 52 | |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Domenic Sacca | Contact | +61 423245187 | domenic.sacca@monash.edu | |
| Raeda Mustafa | Contact | +61 477581540 | raeda.mustafa@monash.edu |
| Name | Affiliation | Role |
|---|---|---|
| Stephen Nicholls, MBBS, FRACP, PhD | VHI | Study Chair |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Monash Health/ Victorian Heart Hospital (VHH) | Recruiting | Clayton | Victoria | 3168 | Australia |
Not provided
| ID | Term |
|---|---|
| D006937 | Hypercholesterolemia |
| D002318 | Cardiovascular Diseases |
| D050197 | Atherosclerosis |
| D009203 | Myocardial Infarction |
| D006973 | Hypertension |
| ID | Term |
|---|---|
| D006949 | Hyperlipidemias |
| D050171 | Dyslipidemias |
| D052439 | Lipid Metabolism Disorders |
| D008659 | Metabolic Diseases |
Not provided
Not provided
This Phase 1 study is designed to characterise safety, tolerability, pharmacokinetics, and pharmacodynamics of STX-1150.
Part 1:
An open-label, single ascending dose will serve to identify the Dose Limiting Toxicities (DLTs) and the Optimal Biological Dose (OBD) of STX-1150.
Part 2:
Following Part 1, an open-label, single or multi-dose expansion of the OBD cohort will be conducted to further characterise the effect of STX-1150.
Not provided
Not provided
Not provided
Not provided
| Percent Change from Baseline in LDL-C |
| Up to 52 weeks |
| Plasma Concentrations of STX-1150 Lipid Components | Up to 52 weeks |
| Number of Participants with Treatment-Induced Immunogenicity | Up to 52 Weeks |
| Absolute Change from Baseline in LDL-C | Up to 52 weeks |
| The Absolute Change from Baseline in Plasma PCSK9 Concentration | Up to Week 52 |
| New Zealand Clinical Research (NZCR) | Not yet recruiting | Christchurch | Christchurch | 8011 | New Zealand |
|
| D009750 |
| Nutritional and Metabolic Diseases |
| D001161 | Arteriosclerosis |
| D001157 | Arterial Occlusive Diseases |
| D014652 | Vascular Diseases |
| D017202 | Myocardial Ischemia |
| D006331 | Heart Diseases |
| D007238 | Infarction |
| D007511 | Ischemia |
| D010335 | Pathologic Processes |
| D013568 | Pathological Conditions, Signs and Symptoms |
| D009336 | Necrosis |